The role of osteopontin expression in melanoma progression

Tumor Biology

Volumn 36, Issue 10, 2015, Pages 7841-7847

  Kiss, Timea ^a   Ecsedi, Szilvia ^a   Vizkeleti, Laura ^a   Koroknai, Viktoria ^a   Emri, Gabriella ^a   Kovács, Nora ^a   Adany, Roza ^a   Balazs, Margit ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Melanoma progression; Osteopontin; Protein expression; Tissue microarray

Indexed keywords

MESSENGER RNA; OSTEOPONTIN; TUMOR MARKER;

ADULT; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; TUMOR VOLUME; DISEASE COURSE; ENZYME IMMUNOASSAY; FOLLOW UP; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; YOUNG ADULT;

ADULT; BIOMARKERS, TUMOR; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; OSTEOPONTIN; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; YOUNG ADULT;

EID: 84944279759     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3495-y     Document Type: Article

References (46)

1. Forschner A, Eigentler TK, Pflugfelder A, Leiter U, Weide B, Held L, et al. Melanoma staging: facts and controversies. Clin Dermatol. 2010;28:275–80.
2. Godar DE (2011) Worldwide increasing incidences of cutaneous malignant melanoma. J Skin Cancer 858425
3. Macdonald JB, Dueck AC, Gray RJ, Wasif N, Swanson DL, Sekulic A, et al. Malignant melanoma in the elderly: different regional disease and poorer prognosis. J Cancer. 2011;2:538–43.
4. Chin L, Garraway LA, Fisher DE. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev. 2006;20:2149–82.
5. Lee B, Mukhi N, Liu D. Current management and novel agents for malignant melanoma. J Hematol Oncol. 2012;5:3.
6. Koh A, da Silva AP, Bansal AK, Bansal M, Sun C, Lee H, et al. Role of osteopontin in neutrophil function. Immunology. 2007;122:466–75.
7. Buback F, Renkl AC, Schulz G, Weiss JM. Osteopontin and the skin: multiple emerging roles in cutaneous biology and pathology. Exp Dermatol. 2009;18:750–9.
8. Wai PY, Kuo PC. Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev. 2008;27:103–18.
9. Rittling SR, Chambers AF. Role of osteopontin in tumour progression. Br J Cancer. 2004;90:1877–81.
10. Sodek J, Ganss B, McKee MD. Osteopontin. Crit Rev Oral Biol Med. 2000;11:279–303.
11. Wang KX, Denhardt DT. Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev. 2008;19:333–45.
12. Hsieh YH, Juliana MM, Hicks PH, Feng G, Elmets C, Liaw L, et al. Papilloma development is delayed in osteopontin-null mice: implicating an antiapoptosis role for osteopontin. Cancer Res. 2006;66:7119–27.
13. Standal T, Borset M, Sundan A. Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol. 2004;26:179–84.
14. Zhou Y, Dai DL, Martinka M, Su M, Zhang Y, Campos EI, et al. Osteopontin expression correlates with melanoma invasion. J Invest Dermatol. 2005;124:1044–52.
15. Weber GF, Lett GS, Haubein NC. Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer. 2010;103:861–9.
16. El-Tanani MK, Campbell FC, Kurisetty V, Jin D, McCann M, Rudland PS. The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev. 2006;17:463–74.
17. Das R, Philip S, Mahabeleshwar GH, Bulbule A, Kundu GC. Osteopontin: it's role in regulation of cell motility and nuclear factor kappa b-mediated urokinase type plasminogen activator expression. IUBMB Life. 2005;57:441–7.
18. Packer L, Pavey S, Parker A, Stark M, Johansson P, Clarke B, et al. Osteopontin is a downstream effector of the pi3-kinase pathway in melanomas that is inversely correlated with functional PTEN. Carcinogenesis. 2006;27:1778–86.
19. Rangaswami H, Bulbule A, Kundu GC. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. 2006;16:79–87.
20. Bellahcene A, Castronovo V, Ogbureke KU, Fisher LW, Fedarko NS. Small integrin-binding ligand n-linked glycoproteins (siblings): multifunctional proteins in cancer. Nat Rev Cancer. 2008;8:212–26.
21. Song G, Ouyang G, Bao S. The activation of akt/pkb signaling pathway and cell survival. J Cell Mol Med. 2005;9:59–71.
22. Shevde LA, Das S, Clark DW, Samant RS. Osteopontin: an effector and an effect of tumor metastasis. Curr Mol Med. 2010;10:71–81.
23. Kazanecki CC, Uzwiak DJ, Denhardt DT. Control of osteopontin signaling and function by post-translational phosphorylation and protein folding. J Cell Biochem. 2007;102:912–24.
24. Rangel J, Nosrati M, Torabian S, Shaikh L, Leong SP, Haqq C, et al. Osteopontin as a molecular prognostic marker for melanoma. Cancer. 2008;112:144–50.
25. Schultz J, Lorenz P, Ibrahim SM, Kundt G, Gross G, Kunz M. The functional -443 T/C osteopontin promoter polymorphism influences osteopontin gene expression in melanoma cells via binding of c-Myb transcription factor. Mol Carcinog. 2009;48:14–23.
26. Tuck AB, Chambers AF, Allan AL. Osteopontin overexpression in breast cancer: knowledge gained and possible implications for clinical management. J Cell Biochem. 2007;102:859–68.
27. Denhardt D. Osteopontin expression correlates with melanoma invasion. J Invest Dermatol. 2005;124:xvi–xviii.
28. Haqq C, Nosrati M, Sudilovsky D, Crothers J, Khodabakhsh D, Pulliam BL, et al. The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A. 2005;102:6092–7.
29. Conway C, Mitra A, Jewell R, Randerson-Moor J, Lobo S, Nsengimana J, et al. Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survival. Clin Cancer Res Off J Am Assoc Cancer Res. 2009;15:6939–46.
30. Rodrigues LR, Teixeira JA, Schmitt FL, Paulsson M, Lindmark-Mansson H. The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:1087–97.
31. Smith AP, Hoek K, Becker D. Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas. Cancer Biol Ther. 2005;4:1018–29.
32. Jaeger J, Koczan D, Thiesen HJ, Ibrahim SM, Gross G, Spang R, et al. Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin Cancer Res Off J Am Assoc Cancer Res. 2007;13:806–15.
33. Mitra A, Conway C, Walker C, Cook M, Powell B, Lobo S, et al. Melanoma sentinel node biopsy and prediction models for relapse and overall survival. Br J Cancer. 2010;103:1229–36.
34. Weber GF. The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta. 2001;1552:61–85.
35. Rakosy Z, Ecsedi S, Toth R, Vizkeleti L, Hernandez-Vargas H, Lazar V, et al. Integrative genomics identifies gene signature associated with melanoma ulceration. PLoS One. 2013;8:e54958.
36. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–8.
37. Koh SS, Opel ML, Wei JP, Yau K, Shah R, Gorre ME, et al. Molecular classification of melanomas and nevi using gene expression microarray signatures and formalin-fixed and paraffin-embedded tissue. Mod Pathol. 2009;22:538–46.
38. Lueking A, Beator J, Patz E, Mullner S, Mehes G, Amersdorfer P. Determination and validation of off-target activities of anti-CD44 variant 6 antibodies using protein biochips and tissue microarrays. Biotechniques. 2008;45:Pi–v.
39. Rud AK, Boye K, Oijordsbakken M, Lund-Iversen M, Halvorsen AR, Solberg SK, et al. Osteopontin is a prognostic biomarker in non-small cell lung cancer. BMC Cancer. 2013;13:540.
40. Cao DX, Li ZJ, Jiang XO, Lum YL, Khin E, Lee NP, et al. Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers. World J Gastroenterol. 2012;18:3923–30.
41. Thoms JW, Dal Pra A, Anborgh PH, Christensen E, Fleshner N, Menard C, et al. Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response. Br J Cancer. 2012;107:840–6.
42. Maier T, Laubender RP, Sturm RA, Klingenstein A, Korting HC, Ruzicka T, et al. Osteopontin expression in plasma of melanoma patients and in melanocytic tumours. J Eur Acad Dermatol Venereol. 2012;26:1084–91.
43. Filia A, Elliott F, Wind T, Field S, Davies J, Kukalizch K, et al. Plasma osteopontin concentrations in patients with cutaneous melanoma. Oncol Rep. 2013;30:1575–80.
44. Kluger HM, Hoyt K, Bacchiocchi A, Mayer T, Kirsch J, Kluger Y, et al. Plasma markers for identifying patients with metastatic melanoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17:2417–25.
45. Raso E, Barbai T, Gyorffy B, Timar J. Prognostic and predictive markers of malignant melanoma. Magy Onkol. 2013;57:79–83.
46. Atai NA, Bansal M, Lo C, Bosman J, Tigchelaar W, Bosch KS, et al. Osteopontin is up-regulated and associated with neutrophil and macrophage infiltration in glioblastoma. Immunology. 2011;132:39–48.